Home / Generics / News

News

Sun Pharma to acquire Ranbaxy creating 5th largest generics firm

India-based Sun Pharmaceutical (Sun Pharma) announced on 6 April 2014 that the company had agreed to acquire rival generics maker Ranbaxy Laboratories (Ranbaxy) in an all-stock deal worth US$3.2 billion.

Taiwan TWi gains FDA approval for generic nifedipine

Taiwan’s TWi Pharmaceuticals (TWi) announced on 7 April 2014 the approval of its abbreviated new drug application (ANDA) for generic nifedipine by the US Food and Drug Administration (FDA).

Dr Reddy’s launches generic amlodipine/atorvastatin

Indian generics giant Dr Reddy’s announced on 27 March 2014 the launch of its generic amlodipine/atorvastatin tablets in the US.

Celecoxib generics could come sooner than expected

Pharma giant Pfizer confirmed on 12 March 2014 that the United States District Court for East Virginia had invalidated its reissue patent covering methods of treating osteoarthritis and other approved conditions with celecoxib, the active ingredient in its blockbuster anti-inflammatory painkiller Celebrex.

Indian generics makers face US recalls

Indian generics makers are once again coming under US Food and Drug Administration (FDA) scrutiny.

FDA approves generic osteoporosis drug

FDA announced on 4 March 2014 that it had approved Teva Pharmaceutical Industries (Teva’s) generic version of Eli Lilly’s osteoporosis drug Evista (raloxifene).

Teva and Ranbaxy settle unlawful competition investigation

New York Attorney General Eric Schneiderman announced on 19 February 2014 that he had reached a settlement with generics makers Ranbaxy Pharmaceuticals (Ranbaxy) and Teva Pharmaceuticals (Teva) for entering into an anti-competitive arrangement.

Gilead to license hepatitis C drug to Indian generics firms

Gilead Sciences (Gilead) has announced plans to license its breakthrough hepatitis C drug Sovaldi (sofosbuvir) to at least three Indian generics manufacturers. The announcement made in February 2014, comes three months after the company faced a ‘patent opposition’ filed at India’s Patent Office, which aimed to block them from gaining a patent for Sovaldi in India.

Sandoz gains Belgian approval for generic inhalation device

In an example of the innovative nature of generics manufacturers, Sandoz, the generics unit of Swiss pharma giant Novartis, announced on 12 February 2014 that it had received marketing authorization in Belgium for AirFluSal Forspiro, an innovative new inhaler for patients with asthma and chronic obstructive pulmonary disease (COPD).

Forest Labs files lawsuit to stop generic memantine

Forest Laboratories and Forest Laboratories Holdings (Forest) announced on 31 January 2014 that the company has filed a lawsuit in the US against several generics makers for their generic versions of Forest’s blockbuster Alzheimer’s disease treatment Namenda XR (memantine).

Generics News Research General

more

Biosimilars News Research General

more